Gardner RC, Burke JF, Nettiksimmons J, Kaup A, Barnes DE, Yaffe K. Dementia risk after traumatic brain injury vs nonbrain trauma: the role of age and severity. JAMA Neurol. 2014;71(12):1490–7.
Lee EB, Kinch K, Johnson VE, Trojanowski JQ, Smith DH, Stewart W. Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players. Acta Neuropathol. 2019;138(3):389–99.
Tateno A, Sakayori T, Takizawa Y, Yamamoto K, Minagawa K, Okubo Y. A case of Alzheimer’s disease following mild traumatic brain injury. Gen Hosp Psychiatry. 2015;37(1):97.e7-97.e9.
Daneshvar DH, Goldstein LE, Kiernan PT, Stein TD, McKee AC. Post-traumatic neurodegeneration and chronic traumatic encephalopathy. Mo Cell Neurosci. 2015;66:81–90.
Mackay DF, Russell ER, Stewart K, MacLean JA, Pell JP, Stewart W. Neurodegenerative disease mortality among former professional soccer players. N Engl J Med. 2019;381(19):1801–8.
Jordan BD. Chronic traumatic brain injury associated with boxing. Semin Neurol. 2000;20:179–85.
Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nat Rev Neurol. 2013;9(4):211–21.
Gentleman SM, Leclercq PD, Moyes L, Graham DI, Smith C, Griffin WST, et al. Long-term intracerebral inflammatory response after traumatic brain injury. In: Forensic Science International. 2004. p. 97–104.
Johnson VE, Stewart W, Smith DH. Axonal pathology in traumatic brain injury. Exp Neurol. 2013;246:35–43.
Sowers JL, Wu P, Zhang K, DeWitt DS, Prough DS. Proteomic changes in traumatic brain injury: experimental approaches. Curr Opin Neurol. 2018;31:709–17.
Song H, Fang S, Gao J, Wang J, Cao Z, Guo Z, et al. Quantitative proteomic study reveals up-regulation of cAMP signaling pathway-related proteins in mild traumatic brain injury. J Proteome Res. 2018;17(2):858–69.
Ganau M, Syrmos N, Paris M, Ganau L, Ligarotti G, Moghaddamjou A, et al. Current and future applications of biomedical engineering for proteomic profiling: predictive biomarkers in neuro-traumatology. Medicines. 2018;5(1):19.
Chen M, Song H, Cui J, Johnson CE, Hubler GK, Depalma RG, et al. Proteomic profiling of mouse brains exposed to blast-induced mild traumatic brain injury reveals changes in axonal proteins and phosphorylated tau. J Alzheimer’s Dis. 2018;66(2):751–73.
Mouzon BC, Bachmeier C, Ferro A, Ojo JO, Crynen G, Acker CM, et al. Chronic neuropathological and neurobehavioral changes in a repetitive mild traumatic brain injury model. Ann Neurol. 2014;75(2):241–54.
Mouzon B, Chaytow H, Crynen G, Bachmeier C, Stewart J, Mullan M, et al. Repetitive mild traumatic brain injury in a mouse model produces learning and memory deficits accompanied by histological changes. J Neurotrauma. 2012;29(18):2761–73.
Morin A, Mouzon B, Ferguson S, Paris D, Saltiel N, Lungmus C, et al. Treatment with nilvadipine mitigates inflammatory pathology and improves spatial memory in aged hTau mice after repetitive Mild TBI. Front Aging Neurosci. 2018;10:292.
Mouzon B, Saltiel N, Ferguson S, Ojo J, Lungmus C, Lynch C, et al. Impact of age on acute post-TBI neuropathology in mice expressing humanized tau: a Chronic Effects of Neurotrauma Consortium Study. Brain Inj. 2018;32(10):1285–94.
Mouzon BC, Bachmeier C, Ojo JO, Acker CM, Ferguson S, Paris D, et al. Lifelong behavioral and neuropathological consequences of repetitive mild traumatic brain injury. Ann Clin Transl Neurol. 2018;5(1):64–80.
Cherry JD, Zeineddin A, Dammer EB, Webster JA, Duong D, Seyfried NT, et al. Characterization of detergent insoluble proteome in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2018;77(1):40–9.
Yuan Y, Zhu C, Liu M, Ke B. Comparative proteome analysis of form-deprivation myopia in sclera with iTRAQ-based quantitative proteomics. Mol Vis. 2021;27:494–505.
Nelvagal HR, Hurtado ML, Eaton SL, Kline RA, Lamont DJ, Sands MS, et al. Comparative proteomic profiling reveals mechanisms for early spinal cord vulnerability in CLN1 disease. Sci Rep. 2020;10(1):1–16.
Kenzie ES, Parks EL, Bigler ED, Wright DW, Lim MM, Chesnutt JC, et al. The dynamics of concussion: mapping pathophysiology, persistence, and recovery with causal-loop diagramming. Front Neurol. 2018;9:203.
Lizhnyak PN, Ottens AK. Proteomics: in pursuit of effective traumatic brain injury therapeutics. Expert Rev Proteomics. 2014;12:75–82.
Ojo JO, Crynen G, Algamal M, Vallabhaneni P, Leary P, Mouzon B, et al. Unbiased proteomic approach identifies pathobiological profiles in the brains of preclinical models of repetitive mild traumatic brain injury, tauopathy, and amyloidosis. ASN Neuro. 2020. https://doi.org/10.1177/1759091420914768.
Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, De Alexandre RB, et al. Clinical and molecular genetics of the phosphodiesterases (pdes). Endocr Rev. 2014;35(2):195–233.
Bender AT, Ostenson CL, Giordano D, Beavo JA. Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phosphodiesterase expression. Cell Signal. 2004;16(3):365–74.
Boess FG, Hendrix M, Van Der Staay FJ, Erb C, Schreiber R, Van Staveren W, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology. 2004;47(7):1081–92.
Domek-Łopacińska K, Strosznajder JB. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res. 2008;24(1216):68–77.
Morin A, Mouzon B, Ferguson S, Paris D, Browning M, Stewart W, et al. Nilvadipine suppresses inflammation via inhibition of P-SYK and restores spatial memory deficits in a mouse model of repetitive mild TBI. Acta Neuropathol Commun. 2020;8(1):166.
Morin A, Mouzon B, Ferguson S, Paris D, Saltiel N, Browning M, et al. A 3-month-delayed treatment with anatabine improves chronic outcomes in two different models of repetitive mild traumatic brain injury in hTau mice. Sci Rep. 2021;11(1):7900.
Nozal V, Martinez A. Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. Eur J Med Chem. 2019;161:39–47.
Lund H, Cowburn RF, Gustafsson E, Strömberg K, Svensson A, Dahllund L, et al. Tau-tubulin kinase 1 expression, phosphorylation and co-localization with phospho-ser422 tau in the Alzheimer’s disease brain. Brain Pathol. 2013;23(4):378–89.
Sato S, Xu J, Okuyama S, Martinez LB, Walsh SM, Jacobsen MT, et al. Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J Neurosci. 2008;28(53):14511–21.
Ojo JO, Bachmeier C, Mouzon BC, Tzekov R, Mullan M, Davies H, et al. Ultrastructural changes in the white and gray matter of mice at chronic time points after repeated concussive head injury. J Neuropathol Exp Neurol. 2015;74(10):1012–35.
Huang FK, Zhang G, Neubert TA. Phosphorylation site profiling of NG108 cells using quadrupole-orbitrap mass spectrometry. In: Neuromethods. 2015. p. 127–41.
Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30(4):523–30.